North American Passive Transdermal Drug Delivery Market Research Report
- Report Code: PA 1001
- Publish Date: Upcoming
The North American passive transdermal drug delivery market, mainly driven by ‘patent cliffs’, increased incidence of chronic diseases, increasing competition, improving patient compliance, reformulation and repositioning of drugs using advanced oral delivery systems, and huge investments made by big pharmaceutical companies, was valued at $6.85 billion in 2013 and is expected to reach $11.33 billion by 2018, at a CAGR of 10.6% from 2013 to 2018.
The U.S. is the world’s largest pharmaceuticals market. It is the world leader in biopharmaceutical research, with approximately 80% of the world’s research & development in biotechnology being conducted by U.S.-based firms. According to the Bureau of Labor Statistics, U.S.A, the pharmaceutical sector employed approximately 272,000 people, and spent $67.4 billion on research & development in 2010. Thus, the well-established pharmaceutical industry in the U.S. is a favorable factor for the growth of the drug delivery market.
The key drivers for the drug delivery market in North America are the robust pharmaceutical industry, large number of pharmaceutical companies and drug delivery technology providers, and the increasing number of collaborations and partnerships between technology providers and pharmaceutical companies. In addition, the growing demand for self-administration and home healthcare devices, along with the increasing applications of inhalers, transdermal patches, and transmucosal systems for chronic disease areas, such as migraine, diabetes, cancer pain, and asthma, has boosted the growth of the market in recent years. Healthcare reforms in the U.S. are expected to have significant impacts on the drug delivery market in the region.
The report also provides an extensive competitive landscaping of the leading companies operating in the market. The main companies in the market include Novartis, Johnson & Johnson, 3M Company, and Noven, among others. Furthermore, segment and country-specific company shares, news & deals, M&A, segment-specific pipeline products, product approvals, and product recalls of the major companies have been detailed in this report.
Customization Options:
Along with the market data, customize the MMM assessments to meet your company’s specific needs. Customize to get a comprehensive summary of the industry standards and deep dive analysis of the following parameters:
Product Analysis
- Usage pattern (in-depth trend analysis) of products (segment-wise)
- Product matrix, which gives a detailed comparison of product portfolio of each company, mapped at country and sub-segment levels
- End-user adoption rate analysis of the products (segment-wise and country-wise)
- A comprehensive coverage of product approvals, pipeline products, and product recalls
Pharmacists Forum
- Fast turn-around analysis of pharmacists’ responses to market events and trends
- Pharmacists’ opinions about passive transdermal drug delivery products from different companies
- Pharmacists’ qualitative inputs on epidemiology data
- Pattern analysis of usage of drugs by physicians
Brand/Product Perception Matrix
- A comprehensive study of customers’ perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogs
- An analysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)
Please fill in the form below to receive a free copy of the Summary of this Report
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
|
|
North American Transdermal Drug Delivery Systems Market The North American Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs using advanced oral delivery systems, huge investment made by big pharmaceutical companies.The Market was Valued at $7.6 billion in 2013 and expected to be $12.7 billion by 2018, growing at a CAGR of 10.9%. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
|
|
European Transdermal Drug Delivery Systems Market The European Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs using advanced oral delivery systems, huge investment made by big pharmaceutical companies.The Market was Valued at $3.6 billion in 2013 and expected to be $5.8 billion by 2018, growing at a CAGR of 9.9 %. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
|
|
Asian Transdermal Drug Delivery Systems Market The Asian Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs using advanced oral delivery systems, huge investment made by big pharmaceutical companies.The Market was Valued at $1.5 billion in 2013 and expected to be $3.0 billion by 2018, growing at a CAGR of 14.8 %. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
